Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 4 Febrile neutropenia risk of CT regimen and additional risk factors per EORTC guidelines (analysis population)

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

  Breast (n = 356) Lung (n = 280) GI: colorectal (n = 103) GI: non-colorectal (n = 72) GYN: ovarian (n = 72) GYN: non-ovarian (n = 39) Head & neck (n = 105) Prostate (n = 66) Other (n = 81) Total (n = 1174)
Patients with CT regimen in EORTC FN risk category, n (%)
 Low (< 10%) 0 (0) 15 (5.4) 0 (0) 0 (0) 28 (38.9) 0 (0) 1 (1) 0 (0) 12 (14.8) 56 (4.8)
 Intermediate (10–20%) 253 (71.1) 139 (49.6) 43 (41.7) 30 (41.7) 2 (2.8) 0 (0) 5 (4.8) 40 (60.6) 1 (1.2) 513 (43.7)
 High (≥ 20%) 12 (3.4) 30 (10.7) 0 (0) 1 (1.4) 2 (2.8) 0 (0) 0 (0) 0 (0) 20 (24.7) 65 (5.5)
 Unknown 91 (25.6) 96 (34.3) 60 (58.3) 41 (56.9) 40 (55.6) 39 (100) 99 (94.3) 26 (39.4) 48 (59.3) 540 (46.0)
Patients with patient-related EORTC risk factor, n (%)
 Age > 65 years 94 (26.4) 120 (42.9) 52 (50.5) 34 (47.2) 42 (58.3) 24 (61.5) 32 (30.5) 53 (80.3) 38 (46.9) 489 (41.7)
 Female gender 351 (98.6) 87 (31.1) 45 (43.7) 26 (36.1) 72 (100) 39 (100) 15 (14.3) 0 (0) 12 (14.8) 647 (55.1)
 Advanced tumour: stage III or IV 199 (55.9) 265 (94.6) 102 (99.0) 66 (91.7) 65 (90.3) 34 (87.2) 90 (85.7) 65 (98.5) 75 (92.6) 961 (81.9)
 ECOG PS ≥ 2* 34 (9.6) 74 (26.7) 8 (8.0) 21 (29.6) 16 (23.5) 4 (11.1) 14 (13.5) 22 (34.4) 20 (25.3) 213 (18.5)
 Haemoglobin level < 12 g/dL* 88 (27.7) 120 (44.8) 44 (44.0) 39 (56.5) 43 (64.2) 25 (67.6) 31 (36.0) 38 (62.3) 42 (53.2) 470 (43.3)
 Prior episode of FN 11 (3.1) 10 (3.6) 3 (2.9) 5 (6.9) 2 (2.8) 0 (0) 1 (1.0) 2 (3.0) 5 (6.2) 39 (3.3)
 Concomitant pathologies with increased risk 11 (3.1) 56 (20.0) 5 (4.9) 4 (5.6) 4 (5.6) 4 (10.3) 9 (8.6) 9 (13.6) 19 (23.5) 121 (10.3)
 No G-CSF use before inclusion 318 (89.3) 270 (96.4) 90 (87.4) 68 (94.4) 64 (88.9) 34 (87.2) 99 (94.3) 60 (90.9) 72 (88.9) 1075 (91.6)
  1. *Some patients had missing data
  2. Liver, renal or cardiovascular disease, according to EORTC definition
  3. Other ST cohorts include urological outside prostate, sarcoma, thymic carcinoma, skin, bone, unknown primary, and multiple independent sites
  4. CT chemotherapy, ECOG PS Eastern Cooperative Oncology Group Performance Status, EORTC European Organisation for Research and Treatment of Cancer, FN febrile neutropenia, G-CSF, granulocyte colony-stimulating factor, GI gastrointestinal, GYN gynaecological, ST solid tumour